PBAC
Ward named as new PBAC chair
Outgoing MSAC chair, Professor Robyn Ward, will take on the leadership of the PBAC this May Professor Ward, the executive dean of the Faculty of Medicine and Health at the …
PBAC backs early supply rule change
Government extends Safety Net early supply rule for 60-day scripts to reduce medicines wastage Changes to the Pharmaceutical Benefits Scheme (PBS) Safety Net early supply rule come into effect today …
Ozempic diabetes competitor gets PBS knockback
Eli Lilly’s Mounjaro would need “substantial price reduction”, says PBAC Mounjaro, the type-2 diabetes medication that the New York Times recently predicted “’could overshadow Ozempic” has been refused funding via …
Guild seeks ‘sensible way forward’ on double dispensing
Community pharmacists are being urged to “keep the pressure on the government” to limit the adverse impacts of 60-day dispensing Government officials need to restart negotiations with community pharmacy leaders …
Double dispensing a breach of trust: Twomey
Trust between the government and community pharmacy is broken, Professor Trent Twomey, Pharmacy Guild of Australia national president believes Labor’s decision to push ahead with its plans for 60-day dispensing …
PBAC ‘has now seen sense’ on fluticasone
The controversial decision to restrict prescribing fluticasone propionate for young children has been reversed in a move welcomed by the Guild But families and pharmacists have been left without clear …
Butler considering 60-day dispensing
Increasing dispensing limits from 30 to 60 days’ supply of medication through the Pharmaceutical Benefits Scheme (PBS) is back on the agenda Ahead of the federal Budget in May, Mark …
Emergency import diabetes drug price stalemate
PBAC gives OK to imports of drought-stricken Ozempic and Trulicity but won’t allow supplier to charge higher price Emergency imported supplies of overseas supplies of shortage-plagued Ozempic (semaglutide) and Trulicity …
High-dose PPI changes ‘effective’: PBAC
Decrease in esomeprazole and increase in pantoprazole scripts likely due to restriction changes, says PBAC, though full picture obscured by lack of OTC and private data Restriction changes established in …
A new recommendation
PBAC recommends listing of adalimumab biosimilar The PBAC has recommended the Authority Required listing of adalimumab (Yuflyma) in the form of 40 mg in 0.4 mL pre-filled syringe and pre-filled …
High doses drop after moves to curb overprescribing
Patients have been shifting to lower dose PPIs following PBS listing changes, review reveals, but more investigation is needed The Drug Utilisation Sub-Committee (DUSC) of the PBAC has found positive …
Keeping up with biosimilars
Pharmacy has a prominent role in the supply and provision of biosimilar medicines, and the profession has been slow to come to terms with this. Is the situation now changing? …